Skip to search formSkip to main contentSkip to account menu

tesamorelin

Known as: GHRH(1-44), N-[(3E)-1-oxo-3-hexenyl]Somatoliberin (human pancreatic islet) 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (2)

EgriftaTH9507

Broader (1)

Somatotropin-Releasing Hormone
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Tesamorelin Modestly Reduces Liver Fat
Tesamorelin (Egrifta), a growth hormone–releasing factor analogue, was approved almost 4 years ago for treatment of HIV… 
2012
2012
Method for purifying tesamorelin
The invention discloses a method for purifying tesamorelin by using a reverse efficient liquid chromatography. The method… 
2010
2010
FDA approves tesamorelin for HIV-related lipodystrophy.
FDA on November 10 announced the approval of tesamorelin, a once-daily injectable treatment to reduce excess abdominal fat in HIV… 
2010
2010
FDA approves tesamorelin for HIV patients with lipodystrophy
Canada-based Theratechnologies announced that FDA has approved tesamorelin (Egrifta) to treat HIV patients with lipodystrophy… 
2010
2010
Tesamorelin Approved for the Treatment of HIV-Related Visceral Adiposity
On November 10, 2010, the FDA approved the growth hormone-releasing factor analogue tesamorelin (Egrifta) for the treatment of… 
2010
2010
Tesamorelin update.
2008
2008
Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.
2008
2008
The next generation of human growth hormone. How Serostim and tesamorelin measure up.
2007
2007
Side effects and complications. Clinical trials of tesamorelin in Canada.
2007
2007
Side effects and complications. Tesamorelin--results from Phase III.